GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (STU:QTS) » Definitions » Cyclically Adjusted PS Ratio

IQVIA Holdings (STU:QTS) Cyclically Adjusted PS Ratio : 3.34 (As of May. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is IQVIA Holdings Cyclically Adjusted PS Ratio?

As of today (2024-05-23), IQVIA Holdings's current share price is €209.70. IQVIA Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €62.85. IQVIA Holdings's Cyclically Adjusted PS Ratio for today is 3.34.

The historical rank and industry rank for IQVIA Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:QTS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.73   Med: 3.58   Max: 5.17
Current: 3.31

During the past years, IQVIA Holdings's highest Cyclically Adjusted PS Ratio was 5.17. The lowest was 2.73. And the median was 3.58.

STU:QTS's Cyclically Adjusted PS Ratio is ranked worse than
60.9% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.35 vs STU:QTS: 3.31

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IQVIA Holdings's adjusted revenue per share data for the three months ended in Mar. 2024 was €18.655. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €62.85 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


IQVIA Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for IQVIA Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings Cyclically Adjusted PS Ratio Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.11 3.34 3.48

IQVIA Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 3.48 2.99 3.48 3.70

Competitive Comparison of IQVIA Holdings's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, IQVIA Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's Cyclically Adjusted PS Ratio falls into.



IQVIA Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

IQVIA Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=209.70/62.85
=3.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IQVIA Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, IQVIA Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=18.655/131.7762*131.7762
=18.655

Current CPI (Mar. 2024) = 131.7762.

IQVIA Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 7.475 100.560 9.795
201409 8.317 100.428 10.913
201412 8.893 99.070 11.829
201503 9.770 99.621 12.924
201506 10.165 100.684 13.304
201509 10.128 100.392 13.294
201512 11.346 99.792 14.982
201603 11.022 100.470 14.456
201606 11.376 101.688 14.742
201609 11.005 101.861 14.237
201612 9.162 101.863 11.853
201703 9.394 102.862 12.035
201706 9.428 103.349 12.021
201709 9.447 104.136 11.955
201712 9.945 104.011 12.600
201803 9.805 105.290 12.272
201806 10.469 106.317 12.976
201809 10.750 106.507 13.301
201812 11.582 105.998 14.399
201903 11.777 107.251 14.470
201906 12.088 108.070 14.740
201909 12.634 108.329 15.369
201912 13.233 108.420 16.084
202003 12.736 108.902 15.411
202006 11.727 108.767 14.208
202009 12.136 109.815 14.563
202012 13.881 109.897 16.645
202103 14.692 111.754 17.324
202106 14.641 114.631 16.831
202109 14.759 115.734 16.805
202112 16.502 117.630 18.487
202203 16.752 121.301 18.199
202206 17.529 125.017 18.477
202209 18.995 125.227 19.988
202212 18.725 125.222 19.705
202303 18.086 127.348 18.715
202306 18.430 128.729 18.866
202309 18.871 129.860 19.150
202312 19.225 129.419 19.575
202403 18.655 131.776 18.655

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IQVIA Holdings  (STU:QTS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


IQVIA Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings (STU:QTS) Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.